Dr Reddy’s Labs Q3 FY25 profit up 2% YoY at Rs. 1,413 Cr
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Total Income in Q2 FY25 stood at Rs. 532.18 crore
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Gross Profit stood at Rs. 36.02 crore compared to Rs. 20.42 crore during Q2FY24, a significant increase of 76.40%
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Subscribe To Our Newsletter & Stay Updated